|
1.Fausto N., a. W. E. Liver regeneration (1994). 2.Shafritz, D. A. Regulation of liver gene expression during various physiologic and pathophysiologic states. Prog Liver Dis 9, 39-55 (1990). 3.Bernuau J, F. G.. Fulminat and subfulminant hepatitis: liver regeneration and prognosis. Liver Regeneration, 147 (1992). 4.Baldwin, A. S., Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107, 3-6 (2001). 5.Fausto, N. & Webber, E. M. Mechanisms of growth regulation in liver regeneration and hepatic carcinogenesis. Prog Liver Dis 11, 115-37 (1993). 6.Michalopoulos, G. K. Liver regeneration: molecular mechanisms of growth control. Faseb J 4, 176-87 (1990). 7.Selden, A. C. & Hodgson, H. J. Growth factors and the liver. Gut 32, 601-3 (1991). 8.Fausto, N. Growth factors in liver development, regeneration and carcinogenesis. Prog Growth Factor Res 3, 219-34 (1991). 9.Fausto, N. & Mead, J. E. Regulation of liver growth: protooncogenes and transforming growth factors. Lab Invest 60, 4-13 (1989). 10.Boyer., Z. Hepatology, A textbook of Liver Disease. 3rd ed 1, 1: 42. (1990). 11.Thorgeirsson, S. S. & Grisham, J. W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31, 339-46 (2002). 12.Beasley, R. P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61, 1942-56 (1988). 13.Tsukuma, H. et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328, 1797-801 (1993). 14.Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6, 273-86 (2007). 15.Aaronson, S. A. Growth factors and cancer. Science 254, 1146-53 (1991). 16.Cross, M. & Dexter, T. M. Growth factors in development, transformation, and tumorigenesis. Cell 64, 271-80 (1991). 17.Folkman, J. & Shing, Y. Angiogenesis. J Biol Chem 267, 10931-4 (1992). 18.Yancopoulos, G. D. et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242-8 (2000). 19.Kuiper, R. A., Schellens, J. H. et al. Clinical research on antiangiogenic therapy. Pharmacol Res 37, 1-16 (1998). 20.McNamara, D. A., Harmey, J. H. et al. Significance of angiogenesis in cancer therapy. Br J Surg 85, 1044-55 (1998). 21.Pluda, J. M. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24, 203-18 (1997). 22.Folkman, J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-6 (1971). 23.Li, X. M., Tang, Z. Y. et al. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 17, 13-7 (1998). 24.Torimura, T. et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 29, 986-91 (1998). 25.Mise, M. et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23, 455-64 (1996). 26.Jinno, K. et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 33, 376-82 (1998). 27.Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175, 409-16 (1972). 28.Shing, Y. et al. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 223, 1296-9 (1984). 29.Sidky Y, A. R. Lymphocyte-induced angiogenesis in tumor-bearing mice. Science 192, 1237-8 (1976). 30.Folkman, J. & Klagsbrun, M. Angiogenic factors. Science 235, 442-7 (1987). 31.Freeman MR., S. F., & Gagnon ML. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. cancer Res 55, 4140-45 (1995). 32.Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-57 (2000). 33.Nakamura, H. et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 183, 273-84 (1989). 34.Hu, T. H. et al. Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 98, 1444-56 (2003). 35.Nakamura, H. et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 269, 25143-9 (1994). 36.Izumoto, Y., Kuroda, T. et al. Hepatoma-derived growth factor belongs to a gene family in mice showing significant homology in the amino terminus. Biochem Biophys Res Commun 238, 26-32 (1997). 37.Everett, A. D. & Bushweller, J. Hepatoma derived growth factor is a nuclear targeted mitogen. Curr Drug Targets 4, 367-71 (2003). 38.Everett, A. D., Stoops, T. et al. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 276, 37564-8 (2001). 39.Kishima, Y. et al. Antisense oligonucleotides of hepatoma-derived growth factor (HDGF) suppress the proliferation of hepatoma cells. Hepatogastroenterology 49, 1639-44 (2002). 40.Bustin, M., Lehn, D. A. & Landsman, D. Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta 1049, 231-43 (1990). 41.Javaherian, K., Sadeghi, M. & Liu, L. F. Nonhistone proteins HMG1 and HMG2 unwind DNA double helix. Nucleic Acids Res 6, 3569-80 (1979). 42.Kuehl, L., Rechsteiner, M. & Wu, L. Relationship between the structure of chromosomal protein HMG1 and its accumulation in the cell nucleus. J Biol Chem 260, 10361-8 (1985). 43.Thanos, D. & Maniatis, T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 71, 777-89 (1992). 44.Reeck, G. R., Isackson, P. J. & Teller, D. C. Domain structure in high molecular weight high mobility group nonhistone chromatin proteins. Nature 300, 76-8 (1982). 45.Einck, L. & Bustin, M. The intracellular distribution and function of the high mobility group chromosomal proteins. Exp Cell Res 156, 295-310 (1985). 46.Mosevitsky, M. I., Novitskaya, V. A. et al. Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur J Biochem 185, 303-10 (1989). 47.Lukasik, S. M. et al. High resolution structure of the HDGF PWWP domain: a potential DNA binding domain. Protein Sci 15, 314-23 (2006). 48.Sue, S. C. et al. PWWP module of human hepatoma-derived growth factor forms a domain-swapped dimer with much higher affinity for heparin. J Mol Biol 367, 456-72 (2007). 49.Yang, J. & Everett, A. D. Hepatoma derived growth factor binds DNA through the N-terminal PWWP domain. BMC Mol Biol 8, 101 (2007). 50.Salvi, A., Arici, B. et al. Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther 3, 671-8 (2004). 51.Clauss, M. et al. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 97, 1321-9 (2001). 52.Kristensen, D. B. et al. Proteome analysis of rat hepatic stellate cells. Hepatology 32, 268-77 (2000). 53.Kawasaki, J., et al. Dissociation between the Ca(2+) signal and tube formation induced by vascular endothelial growth factor in bovine aortic endothelial cells. Eur J Pharmacol 398, 19-29 (2000). 54.Huang, L. et al. HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity. J Biol Chem 274, 38183-8 (1999). 55.Nicosia, R. F., Lin, Y. J. et al. Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am J Pathol 151, 1379-86 (1997). 56.Nicosia, R. F. & Ottinetti, A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 63, 115-22 (1990). 57.Huang, J. & Kontos, C. D. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem 277, 10760-6 (2002). 58.Enomoto, H., Yoshida, K. et al. Participation of hepatoma-derived growth factor in the regulation of fetal hepatocyte proliferation. J Gastroenterol 37 Suppl 14, 158-61 (2002). 59.Kishima, Y. et al. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 277, 10315-22 (2002). 60.Mori, M. et al. Hepatoma-derived growth factor is involved in lung remodeling by stimulating epithelial growth. Am J Respir Cell Mol Biol 30, 459-69 (2004). 61.Everett, A. D., Narron, J. V. et al. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 286, L1194-201 (2004). 62.Everett, A. D., Lobe, D. R., Matsumura, M. E., Nakamura, H. & McNamara, C. A. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 105, 567-75 (2000). 63.Culver, K. W. & Blaese, R. M. Gene therapy for cancer. Trends Genet 10, 174-8 (1994). 64.Culver, K. W. Clinical applications of gene therapy for cancer. Clin Chem 40, 510-2 (1994). 65.Mulligan, R. C. The basic science of gene therapy. Science 260, 926-32 (1993). 66.Yoshida, K. et al. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 13, 159-67 (2006). 67.Chang, K. C. et al. Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer 121, 1059-65 (2007). 68.Yamamoto, S. et al. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 14, 2141-9 (2007). 69.Uyama, H. et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 12, 6043-8 (2006). 70.Iwasaki, T. et al. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep 13, 1075-80 (2005). 71.Ren, H. et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 22, 3230-7 (2004). 72.Yamamoto, S. et al. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 12, 117-22 (2006). 73.Lauffenburger, D. A. Cell motility. Making connections count. Nature 383, 390-1 (1996). 74.Friedl, P. & Wolf, K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3, 362-74 (2003). 75.Bernard, K. et al. Functional proteomic analysis of melanoma progression. Cancer Res 63, 6716-25 (2003). 76.Lepourcelet, M. et al. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development 132, 415-27 (2005). 77.Plate, K. H., Breier, G. et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848 (1992). 78.Beck, L. a. D., P.A. Vascular development: cellular and molecular regulation. FASEB J. 11, 365-373 (1997 ). 79.Carmeliet, P., Ferreira, V. et al. and Eberhardt, C. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996). 80.Okuda, Y. et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 94, 1034-41 (2003). 81.Grosjean, J., Kiriakidis, S. et al. Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. Biochem Biophys Res Commun 340, 984-94 (2006). 82.Sasaki, H., Ray, P. S. et al. Oxidative stress due to hypoxia/reoxygenation induces angiogenic factor VEGF in adult rat myocardium: possible role of NFkappaB. Toxicology 155, 27-35 (2000). 83.Chiarugi, V., Magnelli, L. et al. Hypoxia induces pivotal tumor angiogenesis control factors including p53, vascular endothelial growth factor and the NFkappaB-dependent inducible nitric oxide synthase and cyclooxygenase-2. J Cancer Res Clin Oncol 125, 525-8 (1999). 84.Graham, F. L. & Prevec, L. Methods for construction of adenovirus vectors. Mol Biotechnol 3, 207-20 (1995). 85.Yeo, M. et al. Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis. Gut 55, 26-33 (2006). 86.McKillop, I. H., Moran, D. M. et al. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res 136, 125-35 (2006). 87.Curran, S. & Murray, G. I. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36, 1621-30 (2000). 88.Fridman, R., Toth, M. et al. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 55, 2548-55 (1995). 89.Yoshida, K. et al. Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J Gastroenterol Hepatol 18, 1293-301 (2003). 90.Zhang, J. et al. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 66, 18-23 (2006). 91.Guinebretiere, J. M. [Angiogenesis and breast neoplasms. The pathologist''s point of view]. Gynecol Obstet Fertil 33, 140-6 (2005). 92.Folkman, J. Tumor angiogenesis. Adv Cancer Res 43, 175-203 (1985). 93.Ryschich, E. et al. Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res 66, 198-211 (2006). 94.O''Byrne, K. J., Dalgleish, A. G. et al. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 36, 151-69 (2000). 95.Folkman, J. The role of angiogenesis in tumor growth. Semin Cancer Biol 3, 65-71 (1992). 96.Oliver, J. A. & Al-Awqati, Q. An endothelial growth factor involved in rat renal development. J Clin Invest 102, 1208-19 (1998). 97.Shi, C. S. et al. Evidence of human thrombomodulin domain as a novel angiogenic factor. Circulation 111, 1627-36 (2005). 98.O''Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-85 (1997). 99.Jimenez, B. et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6, 41-8 (2000). 100.Wu, J. T. & Kral, J. G. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 123, 158-69 (2005). 101.Karihtala, P. & Soini, Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. Apmis 115, 81-103 (2007). 102.Culotta, V. C., Yang, M. et al. Activation of superoxide dismutases: putting the metal to the pedal. Biochim Biophys Acta 1763, 747-58 (2006). 103.Tsanou, E. et al. Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinoma. Histol Histopathol 19, 807-13 (2004). 104.Sikka, S. C. & Hellstrom, W. J. Role of oxidative stress and antioxidants in Peyronie''s disease. Int J Impot Res 14, 353-60 (2002). 105.Carter, C. D., Kitchen, L. E. et al. Loss of SOD1 and LYS7 sensitizes Saccharomyces cerevisiae to hydroxyurea and DNA damage agents and downregulates MEC1 pathway effectors. Mol Cell Biol 25, 10273-85 (2005). 106.Ushio-Fukai, M. & Alexander, R. W. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem 264, 85-97 (2004). 107.Xia, C. et al. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 67, 10823-30 (2007). 108.Guastalla, J. P., Bachelot, T. et al. [Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials]. Bull Cancer 91 Suppl 2, S99-108 (2004). 109.Jones, D. A., Carlton, D. P. et al. Zimmerman, G. A. & Prescott, S. M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 268, 9049-54 (1993). 110.Han, C., Michalopoulos, G. K. et al. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 207, 261-70 (2006). 111.Sano, H. et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55, 3785-9 (1995). 112.Molina, M. A., Sitja-Arnau, M. et al.Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59, 4356-62 (1999). 113.Koga, H. et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29, 688-96 (1999). 114.Zhao, Q. T. et al. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci 80, 484-92 (2007). 115.Lilienbaum, A. & Israel, A. From calcium to NF-kappa B signaling pathways in neurons. Mol Cell Biol 23, 2680-98 (2003). 116.Kane, L. P., Shapiro, V. S. et al. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 9, 601-4 (1999). 117.Beraud, C., Henzel, W. J. et al. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci U S A 96, 429-34 (1999). 118.Jones, P. F., Jakubowicz, T. et al. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A 88, 4171-5 (1991). 119.Hayakawa, J. et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60, 5988-94 (2000). 120.Imrich, A., Ning, Y. Y. et al. Intracellular oxidant production and cytokine responses in lung macrophages: evaluation of fluorescent probes. J Leukoc Biol 65, 499-507 (1999). 121.Guo, Y. S. et al. Synergistic Regulation of COX-2 Expression by Bombesin and Transforming Growth Factor-beta. Dig Dis Sci (2007). 122.Waris, G. & Siddiqui, A. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol 79, 9725-34 (2005). 123.Bonavida, B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 26, 3629-36 (2007). 124.DeWire, S. M., Ahn, S. et al. Beta-arrestins and cell signaling. Annu Rev Physiol 69, 483-510 (2007). 125.Hunzelmann, N., Eming, S. et al. [Growth factors]. Z Rheumatol 66, 290, 292-6 (2007). 126.Yano, S. et al. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol 11, 73-81 (2006). 127.Gupta, R. A. & Dubois, R. N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1, 11-21 (2001). 128.Kondo, M. et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 5, 4005-12 (1999). 129.Ikeda, T., Tozuka, S. et al. Prostaglandin-E-producing hepatocellular carcinoma with hypercalcemia. Cancer 61, 1813-4 (1988). 130.Leng, J., Han, C. et al. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38, 756-68 (2003). 131.Jiang, B. H. & Liu, L. Z. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta (2007). 132.Jackson, C. J. & Nguyen, M. Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. Int J Biochem Cell Biol 29, 1167-77 (1997).
|